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The role of conjugation of chemicals and endogenous compounds is an important 
mechanism in detoxification and metabolic signaling. Specifically, amidation, 
sulfonation, and glucuronidation are necessary functions of the human body. Exposure 
to environmental toxins such as bisphenols must be conjugated in order to be excreted 
from the body. Bisphenol A was originally developed as a synthetic estrogen, however 
later found use as a monomer within the plastics industry allowing for wide-spread 
exposure to BPA through food and drink containers. While most healthy individuals 
are capable of metabolizing and excreting bisphenol A, this metabolism can be 
impacted by diet and disease. Herein, the effects of obesity and fasting are shown to 
reduce the capacity of BPA glucuronidation in wild-type and ob/ob mice. In addition 
to environmental toxins, endogenous compounds such as bile acids can undergo 
sulfonation, amidation, and glucuronidation. Occasionally, drugs can cause drug-
induced liver injury, often leading to cholestasis that can cause permanent liver injury 
if the drug is not stopped. The buildup of bile acids within the liver can then lead to 
liver damage because bile acids are amphiphilic compounds that act as strong 
detergents, capable of breaking down the hepatocellular membrane. In order to combat 
this build up toxic bile acids, conjugation occurs to increase the polarity and water 
solubility of the bile acids, thus leading to increased excretion. I proposed that drugs 
may inhibit the sulfonation of lithocholic acid (LCA), the most toxic bile acid, or 
inhibiting the amidation of other bile acids (the predominate form of bile acids) 
leading to drug induced liver injury. LCA sulfonation is catalyzed by human cytosolic 
sulfotransferase (SULT) 2A1. Bile acid amidation is catalyzed by human bile acid 
 
 
coenzyme A synthetase/bile acid coenzyme A: amino acid N-acyltransferase 
(BACS/BAAT).  In this study, 125 drugs were screened for inhibition of SULT2A1 
and the BACS/BAAT enzymes. I successfully identified several compounds as potent 
SULT2A1 inhibitors. While only a single inhibitor of amidation was discovered, I 
developed a novel one step enzymatic assay to test for the inhibition of BACS and 
BAAT. While drugs can cause cholestasis as an unwanted effect, a class of drugs 
called fibrates are being studied for use in treatment of primary biliary cholangitis 
(PBC) and primary sclerosing cholangitis (PSC). Fibrates are known peroxisome 
proliferator-activated receptor (PPAR) activators, and in this study, I proposed the use 
of fenofibrate in patients with PBC and PSC will reduce serum liver enzymes and bile 
acids. In both patient cohorts, we observed large decreases in serum bile acids, 
particularly conjugated bile acids, and the bile acid precursor 7α-hydroxy-4-cholesten-
3-one (C4). In addition, we observed a shift from the classic synthesis pathway of bile 
acids towards an alternative pathway of chenodeoxycholic acid (CDCA) synthesis. 
These results suggest the downregulation of bile acid synthesis and the BACS/BAAT 
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Bisphenol A (BPA) is a widely used monomer and known endocrine disruptor. 
Exposure to BPA is widespread and is metabolized by the liver through sulfonation 
and glucuronidation. BPA and obesity have been previously linked and thus BPA 
glucuronidation may be impaired in obese individuals. 
Objectives 
To determine the effects of fasting and obesity on BPA glucuronidation in mouse 
liver. 
Methods 
The capacity for BPA glucuronidation was determined in wild-type and in ob/ob 
mouse liver in both a fasted and fed state, and subsequently quantified by HPLC-UV. 
Results 
Compared to fed wild type mice (100%), BPA glucuronidation was reduced to 60% in 
wild type fasted mice, 39% in fed ob/ob mice, and 46% in fasted ob/ob mice. In 
addition, it was determined that two UGTs in mouse liver are responsible for BPA 
glucuronidation, a low Km and a high Km UGT. 
Conclusion 
These findings indicate that the capacity of BPA metabolism through glucuronidation 











BPA   bisphenol A 
BPA-G  bisphenol A-glucuronide 
MRP   multidrug resistance-associated protein 
SULT   sulfotransferase 
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Bisphenol A (BPA), a synthetic industrial chemical within a larger group of 
bisphenols, is a potential endocrine disruptor with extensive exposure in humans. BPA 
was first synthesized in 1891 by Alexander Dianin (Dianin, 1891) and its estrogenic 
properties were later discovered in 1936 but considered a weak estrogen compared to 
other compounds (Dodds and Lawson, 1936). It was later identified as a monomer in 
polycarbonate plastics often used in plastic bottles, food cans, shampoo, lotion, soap, 
epoxy resins, and dental sealants with the dietary exposure being the primary source of 
human exposure (Shelby, 2008; Dodson et al., 2012). In 2003, in a study of over 2,000 
participants, 92.6% had detectable concentrations of BPA in urine (Calafat et al., 
2008).  
 
Several studies have linked BPA to potential learning impairments (Mhaouty-Kodja et 
al., 2018), dysregulation of the estrous cycle (Viguie et al., 2018), and metabolic 
diseases including diabetes and obesity (Le Magueresse-Battistoni et al., 2018). BPA 
and obesity had been associated as early as 2001 (Rubin et al., 2001), but the 
mechanism of action was not well understood until recently. Ke and coworkers 
observed mice exposed to BPA for 10 months showed accumulation of hepatic 
triglycerides and cholesterol (Ke et al., 2016). These effects were attributed to 
reprograming of the DNA methylation patterns of Srebf1 and Srebf2 (Sterol 
Regulatory Element Binding Transcription Factor). Another study has linked an 
increase in de novo fatty acid synthesis to BPA exposure, following a nonmonotonic 




study of approximately 3400 Chinese patients showed that high urinary BPA 
concentration was positively associated with increased obesity and insulin resistance 
(Wang et al., 2012). Because of these findings, investigation into the metabolism of 
BPA in diseased states is warranted. 
 
BPA is primarily metabolized in the liver through sulfate and glucuronidation 
conjugates which are then eliminated through urine or feces (Pritchett et al., 2002; 
Hanioka et al., 2008).  BPA can exist as either a mono- or di-sulfate but both are 
minor metabolites compared to BPA-glucuronide (BPA-G) in both humans and 
rodents (Nishiyama et al., 2002; Volkel et al., 2002; Teeguarden et al., 2015; Thayer 
et al., 2015). In humans, urinary excretion is the predominate pathway of elimination, 
but in rodents, most BPA-G is eliminated through feces (Kurebayashi et al., 2003) 
possibly because BPA-G shows high affinity for rodent mrp2, allowing for BPA-G to 
enter the bile duct (Mazur et al., 2012). In humans, BPA-G shows affinity for MRP3 
(multidrug resistance-associated protein) but not MRP2, accounting for species 
differences in elimination (Mazur et al., 2012). In rodents, conjugated BPA has been 
shown to be deconjugated and undergo enterohepatic recirculation unlike humans 
(Sakamoto et al., 2002; Doerge et al., 2010) but two other studies have shown similar 
pharmacokinetics between primates and mice, suggesting that rodents are still a 
relevant model for BPA elimination (Tominaga et al., 2006; Taylor et al., 2011). 
 
The sulfonation of BPA occurs through a class of phase-II detoxification enzymes 




sulfotransferase 1A1/1A3 (SULT1A1/1A3), and hepatic sulfonation of BPA has been 
shown to be reduced in diseased livers and obese mice (Yalcin et al., 2016). The 
demonstration of sulfonation being decreased in obese mice suggests that BPA 
glucuronidation may also be altered in obesity. Indeed, test subjects with high BMI 
exhibited higher serum BPA levels than low BMI subjects after oral exposure to a test 
dose of BPA (Nishiyama et al., 2002; Volkel et al., 2002; Teeguarden et al., 2015; 
Thayer et al., 2015). Glucuronidation occurs through a class of enzymes called UDP-
glucuronosyltransferases (UGT) which adds a glucuronide moiety to a variety of 
substrates such as NSAIDs (nonsteroidal anti-inflammatory drugs), opioids, anti-
psychotics, anti-depressants, and contraceptives (Coffman et al., 1998; Liston et al., 
2001; Edelman et al., 2010). The UGT family is divided into two subgroups, UGT1 
and UGT2 each containing several isoforms. In humans, BPA is believed to be 
metabolized by UGT2B15 and in rodents by ugt2B1 in rodents (Yokota et al., 1999; 
Hanioka et al., 2008). In a recent study, researchers knocked out the UGT2 family in 
mice, yet still observed BPA being glucuronidated, with only minor differences 
compared to wild-type (Fay et al., 2015). The results of this study suggest that, in 
mice, the UGT1 family is partially responsible for BPA glucuronidation. Expression 
of the UGT2 family in rats has been shown to be tied to age, and specifically 
UGT2B15 in humans, which raises concerns of BPA exposure in pregnant females or 
young children (Coughtrie et al., 1988; Divakaran et al., 2014). The effects of obesity 
on UGT expression is filled with conflicting results, some demonstrating an increase 
in UGT activity, some reporting no change, and other showing decreases as reviewed 




decrease of BPA glucuronidation in liver tissue from obese mice, and show that more 
than one UGT may be responsible for glucuronidation.   
 
 
MATERIALS AND METHODS 
 
Chemicals  
HPLC grade solvents and all reagents for microsomal preparation were purchased 
from Fisher Scientific (Waltham, MA). Bisphenol A and uridine 5′-
diphosphoglucuronic acid (UDPGA) were purchased from Millipore Sigma 
(Burlington, MA). Bisphenol A glucuronide was purchased from Toronto Research 
Chemicals (North York, ON, Canada).  
 
Animal treatment and fasting 
Adult male 8 week old C57BL/6 (WT, n=8/group) and Lep−/− (B6.V-Lepob/J, ob/ob, 
n=8/group) (Jackson Laboratories, Bar Harbor, ME, USA) were ad libitum fed Harlan 
TekladLM-485 Mouse/Rat sterilizable diet. Fasted mice had food withheld for 24 
hours immediately before sacrifice. Mice were housed in cages with corncob bedding, 
in a humidity, light and temperature-controlled environment within Fogarty Hall at the 
University of Rhode Island, Kingston, RI. IACUC approval was obtained prior to start 
of experiments. Livers were collected and snap frozen in liquid nitrogen and stored at -







Microsome isolation from mouse liver tissue  
Approximately 150 mg of previously collected tissue was homogenized and prepared 
as previously reported (Yalcin et al., 2013). Briefly, tissue was homogenized in 
sucrose/Tris/EDTA/BHT buffer and centrifuged to separate cytosolic and microsomal 
fractions. The microsomal pellet was resuspended by sonication in buffer containing 
0.25M Sucrose, 10mM Tris-HCl (pH-7.8), 1mM EDTA, 20μM BHT and 20% 
glycerol. Protein concentrations were determined by Nano Drop ND1000 at 280 nm 
(Thermo Fisher Scientific, Waltham, MA) 
 
BPA-glucuronidation assay 
Glucuronidation assays for each liver microsome sample was performed in triplicate, 
with the average of the data being analyzed. The assay was optimized to ensure 
linearity with regards to all aspects. Mouse liver microsome (0.05 mg/mL) was 
incubated with 2 mM uridine diphosphate glucuronic acid (UDPGA) and various 
concentrations of BPA (1 to 50 μM) in 20 mM potassium phosphate (pH 7.0). 
Reaction was incubated at 37oC for 15 min, then stopped by placing in boiling water 
for 30 sec, and centrifuging at 15,000 x g for 15 minutes to pellet the protein. BPA and 
BPA-G were quantified by HPLC with UV detection. 20 µl of reaction mixture was 
injected onto an Agilent Zorbax SB-Aq column (150 x 4.6 mm, 5 μm) (Santa Clara, 
CA) connected to a Hitachi LaChrome Elite HPLC with a L-2450 diode array detector 
(Tokyo, Japan). Mobile phase A consisted of 20 mM potassium phosphate buffer (pH 
2.7), and mobile phase B consisted of acetonitrile. A linear gradient of B over 2 




4 minutes at a flow rate of 1 mL/min was used to analyze BPA (6.6 min) and BPA-G 
(4.8 min) at 200 nm.  
 
Statistical Analysis 
Group comparisons were analyzed for statistical significance by ANOVA in GraphPad 
Prism 8 (La Jolla, CA). Km and Vmax were calculated with an n = 8, in triplicates per 
group with Prism 8’s non-linear kinetics (Michaelis-Menten and two enzyme model) 
function. Best fit model was determined by Akaike criterion by comparing different 





BPA was separated from BPA-G as described in Methods. BPA had a retention time 
of 6.6 min, and BPA-G had a retention time of 4.8 min (Figure 1). A calibration curve 
of BPA-G from 0.1 μM to 10 μM was used to convert BPA-G peak area to 
concentration of BPA-G (μM). This curve was used to quantify BPA-G in the 
glucuronidation assay mixture with microsomal fraction from liver tissue of 32 mice 
(n=8 per group): wild type fed, wild type fasted, ob/ob fed, and ob/ob fasted. The data 
from various BPA concentrations were then put into GraphPad Prism to determine the 
best fit model by comparing Michaelis-Menten models and a two-enzyme model by 
Akaike criterion (Table 1). The two-enzyme model was determined to be the best fit to 
determine Km and Vmax. The kinetic parameters for the higher (10-50 μM BPA) could 
be elucidated, but the model was unable to determine the Km and Vmax for the other 




Burke plots for both the high and low Km are shown to further demonstrate the two 
different isoforms present (Figure 3). A single enzyme Michaelis-Menten model of 1-
2 μM BPA was used to determine approximate Km and Vmax for the lower range 
(Figure 4). BPA glucuronidation in wild type mice at 30 μM BPA averaged 449.7 
pmol/min/mg and subsequently reduced to 60% in wild type fasted mice, 39% in fed 
ob/ob mice, and 46% in fasted ob/ob mice (Figure 5).  Increased free fatty acids and 
triglycerides in both serum and the liver are characteristics of obesity. In order to 
better understand if glucuronidation is correlated to these characteristics, Pearson 
correlations were conducted with the calculated Vmax values. The measured fatty acids 
and triglycerides were previously measured and published by our group (Figure 6) 
(Yalcin et al., 2016).  BPA glucuronidation demonstrates significant inverse 
correlation with liver triglycerides and serum free fatty acids (Figure 6A, 6D).  
 
DISCUSSION 
In this study we demonstrate the effects of obesity and fasting on wild type and ob/ob 
mice. With the use of the Akaike criterion and a Lineweaver-Burke plot, based on our 
results there are two different isoforms of Ugt capable of BPA glucuronidation. The 
lower Km value could not be fully elucidated from the two-enzyme model as not 
enough data points were measured at such a low concentration. We thus used a typical 
Michaelis-Menten graph in order to better estimate the Km of this Ugt to 
approximately 2 μM. The two-enzyme model was used in the 10-50 μM range to 
determine the higher Km of 13.3 μM and 17.8 μM in WT and ob/ob mice respectively.  




model was produced, but mice retained the majority of their capacity to conjugate 
BPA (Fay et al., 2015). Human data demonstrated the highest activity of BPA 
glucuronidation by UGT2B15 at under 5 μM (80%) where at higher concentrations 
UGT1A9 becomes the predominate isoform for glucuronidation (Street et al., 2017).  
While most studies examine the metabolism of BPA in rats, BPA is metabolized by 
different UGTs than that in mice (Ugt1a9, Ugt2b1) and humans (UGT1A9, 
UGT2B15). Thus, the potential Ugts of BPA glucuronidation are Ugt1a9 and Ugt2b1. 
While more studies using recombinant mouse enzymes or specific Ugt inhibitors 
would be needed to confirm the specific Ugts responsible for mouse glucuronidation, 
the identification of these would allow for better use of a mouse model in BPA 
metabolism.  
 
Overall, we observed large reductions in Ugt activity in fasting and obese models 
compared to WT. These large reductions in capacity to metabolize BPA are 
concerning as BPA is a known endocrine disruptor. Reductions in conjugation of BPA 
will result in a large AUC of BPA. While fasting appeared to reduce conjugation in 
the WT mice, this reduction was no observed in the obese mice. Short term fasting is 
known to increase liver triglycerides and in mice can lead to hepatic steatosis (Guan et 
al., 2009). This explains why there were smaller reductions between the fasted WT 
mice and the fed obese mice, as their livers were in a similar state. In addition, the 
addition of fasting did not promote anymore significant loss of conjugation as the 





While we observed a reduced capacity of BPA glucuronidation in this study, and 
reduced sulfonation in our previous work (Yalcin et al., 2016), this does not fully 
agree with previous mRNA data showing an upregulation of Ugt1a9 in mRNA in 
obese and fasting states while Ugt2b1 is downregulated by obesity but upregulated in 
fasting (Xu et al., 2012). UGT activity was also tested within the same study using 
acetaminophen, a known UGT1A9 substrate, and more closely matches our current 
data. The mRNA does not appear to correlate to the activity of the Ugts suggesting 
translational and post-translational issues could be at play. Additional studies with 
proteomics work on these livers could elucidate the potential mechanism in this 
system. 
 
In summary, we report a significant decrease in BPA glucuronidation in obese and 
fasted mice and that two different isoforms are responsible for glucuronidation in 
mice. At low concentrations of BPA, one isoform is the predominate UGT, while at 
higher concentrations, a presumably less specific UGT can metabolize BPA. This 
suggests that obesity may increase BPA exposure through a reduction in conjugation 
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Figure 1. Separation on an Agilent Zorbax SB-Aq column. Detection was by UV at 
200 nm. Bisphenol A-glucuronide was eluted with a mobile phase linear gradient of 







Figure 2. Two Enzyme Model (V/S). Evaluation of BPA glucuronidation rates over a 
range of BPA substrate concentrations (1 uM to 50 uM) to enable kinetic constant 
determination. All points were the average of 8 mice in triplicates. Best fit model was 
determined by Akaike criterion by comparing different models relative to each other. 
 





































Figure 3. Lineweaver-Burke (1/v vs 1/s) plot. Indicates multiple isoforms contribute 
to BPA glucuronidation in mouse liver microsomes. All points were the average of 8 



















Figure 4. Michaelis-Menten Plot (1-2 uM) (V/S). Evaluation of BPA glucuronidation 
over a range of BPA from 1 uM to 2 uM to enable kinetic constant determination. All 
points were the average of 8 mice in triplicates.  
 





































Figure 5. Comparison of mouse BPA glucuronidation activity in wild type (WT) 
versus obese (ob/ob). BPA glucuronidation activity was determined by incubating 30 
µM BPA with mouse liver cytosol for 15 min in the presence of 2 mM UDPGA and 
20 mM potassium phosphate pH 7.0. Different letters indicate statisical significance 
between the groups (p<0.05), with similar letters indicating not statisicially 
significant. 


































Figure 6. Correlation of BPA glucuronidation (Vmax) in WT and ob/ob mice under 
both fed and fasted states (n=8/group) with (A) liver triglycerides (mg/g liver wt), (B) 
liver free fatty acids (uEq/g liver wt), (C) serum triglycerides (mg/dL), and (D) serum 
free fatty acids (mEq/L). Correlations were obtained in GraphPad Prism 8 by Pearson 










Table 1. A test was run to determine the best fit model for the data by checking the 
Akaike criterion. The model with the lower AIC values are the best fit models for the 
data. P < 0.05 were considered significant. 
 
WT fed WT fasted Ob/Ob fed Ob/Ob fasted
One Enzyme Model AIC 1995 1780 1449 1597
Two Enzyme Model AIC 1962 1756 1433 1585
Preferred Model Two Enzyme Two Enzyme Two Enzyme Two Enzyme





Table 2. Calculated kinetic parameters of the two-enzyme model for the higher Km 
isoform. Vmax is expressed in pmol*min
-1*mg-1. Km is expressed in μM.  
 
Vmax Km
C57Bl/6 fed 493.0 13.2
C57Bl/6 fasted 292.4 13.4
Ob/Ob fed 253.1 17.4
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BACS   bile acid coenzyme A synthetase 
BAAT   bile acid coenzyme A: amino acid N-acyltransferase 
Bsep   bile salt export pump 
C4   7α-hydroxy-4-cholesten-3-one 
CA   cholic acid 
CDCA   chenodeoxycholic acid 
CYP   cytochrome P450 
DCA   deoxycholic acid 
DILI   drug-induced liver injury 
LCA   lithocholic acid 
LCA-S   lithocholic acid sulfate 
LC-MS  liquid chromatography-mass spectrometry 
NHR   nuclear hormone receptors 
NSAID  nonsteroidal anti-inflammatory drug 
PAPS   3'-phosphoadenosine-5'-phosphosulfate 
SULT   sulfotransferase 
TCA   taurocholic acid 
UGT   uridine 5'-diphospho-glucuronosyltransferase 







Hepatic bile acid conjugation is a crucial function of human liver, and inhibition of 
bile acid metabolism can lead to potential liver injury through bile acid retention. 
Because drug-induced liver injury (DILI) is one of the most frequent reasons for drug 
withdrawal and mechanisms for DILI of some drugs are unknown, there is potential of 
DILI to be mediated through inhibition of bile acid amidation and sulfonation. We 
investigated 125 compounds for their potential inhibition of lithocholic acid 
sulfonation and cholic acid amidation. Enzymatic assays were developed for human 
sulfotransferase 2A1 (SULT2A1) and bile acid coenzyme A synthetase and bile acid 
coenzyme A: amino acid N-acyltransferase (BACS/BAAT). The two-step bile acid 
amidation was conducted in a single incubation mixture using human S9 fractions. 
Samples were analyzed by LC/MS/MS, and data were analyzed using non-linear 
regression to determine inhibition (IC50) values. Of 125 compounds tested for 
inhibition of LCA-sulfonation, nine had IC50 values less than 100 μM (range 0.73 – 
99 M), of which four are known to cause liver injury. Only one compound inhibited 
bile acid amidation (IC50 70 μM). Based on the results of this study, it does not 
appear inhibition of sulfonation or amidation is a significant cause of drug induced 
liver injury, but several new sulfotransferase 2A1 inhibitors were discovered, and a 






Hepatic bile acid synthesis, secretion, and conjugation are crucial functions of the 
human liver. Bile acids are amphiphilic molecules derived from cholesterol with 
important roles in metabolic signaling, absorption of lipids, cholesterol, fat and fat- 
soluble vitamins. However, over-accumulation of the detergent-like bile acids within 
the liver can be cytotoxic, leading to inflammation, fibrosis, cholestasis, cirrhosis, and 
liver failure. Excess bile acids have been shown to break down the cell membranes of 
hepatocytes (Scholmerich et al., 1984; Attili et al., 1986) and alter the membrane 
permeability transition of the mitochondria, leading to apoptosis or necrosis (Gores et 
al., 1998; Rolo et al., 2000).  
 
The intrahepatic buildup of bile acids can be caused by several different mechanisms, 
but one of particular concern is as a side effect of drugs.  The cause of this drug-
induced liver injury (DILI) is often attributed to Bile Salt Export Pump (Bsep) 
inhibition, for example rifampicin, cyclosporin A, rifamycin, bosentan, and 
troglitazone leading to cholestasis in rats (Bohme et al., 1993; Stieger et al., 2000; 
Fattinger et al., 2001; Funk et al., 2001). Other DILI-associated drugs target the bile 
duct epithelium leading to vanishing bile duct syndrome (VBDS) also called drug-
induced bile duct injury. VBDS refers to the destruction and disappearance of 
intrahepatic bile ducts which ultimately results in cholestasis (Reau and Jensen, 2008). 
While the effects of VBDS are sometimes permanent, often discontinuation of 
exposure to the drug causing VBDS can stop the progression and in some cases, 




a subset of patients experience liver injury (Ortega-Alonso and Andrade, 2018) and 
once drug treatment is ceased, most patients’ biomarkers return to normal, but some 
patients experience progressive and more permanent injury (Navarro and Senior, 
2006).  
 
Bile acid concentrations in the liver tissue are controlled by the combination of 
synthesis, secretion and conjugation. Bile acid synthesis occurs through one of two 
pathways, with the most common pathway being synthesis from cholesterol by the 
cytochrome P450 (CYP) enzymes, specifically cytochrome P450 7A1 (CYP7A1) to 
7α-hydroxy-4-cholesten-3-one (C4), leading to the synthesis of cholic acid (CA) or 
chenodeoxycholic acid (CDCA) by CYP8B1 and CYP27A1, respectively (Chiang, 
2004). The alternative pathway bypasses C4 and only produces CDCA by 
metabolizing cholesterol into 27-hydroxycholesterol via CYP7B1 (Chiang, 2004). 
Both CA and CDCA undergo conjugation to a polar group or reductive metabolism. 
Reductive metabolism into a secondary bile acid, i.e. deoxycholic acid (DCA) or 
lithocholic acid (LCA), is catalyzed by bacterial enzymes within the intestinal 
microflora (Hirano et al., 1981; Wells et al., 2000; Wells et al., 2003).  
 
The majority of bile acids in vivo exist in a conjugated state which functions to alter 
the physiochemical properties by conjugation with taurine, glycine, sulfate or 
glucuronide, reducing hydrophobicity and toxicity through an increase in polarity 
(Trottier et al., 2011; Trottier et al., 2012). Amidation occurs through sequential action 




reticulum, and bile acid coenzyme A: amino acid N-acyltransferase (BAAT) in the 
cytosol (Killenberg, 1978). The process of amidation adds an amine, i.e. taurine or 
glycine, to the carboxylic acid moiety of the unconjugated bile acid, enhancing 
aqueous solubility.  Alternatively, glucuronidation adds a glucuronide to one of 
several sites containing an -OH moiety on the bile acid, resulting in a more 
hydrophilic and readily excreted compound. A specific uridine 5'-diphospho-
glucuronosyltransferase (UGT) enzyme catalyzes the glucuronidation reaction, 
depending upon the particular -OH site of glucuronidation (Gall et al., 1999; Barbier et 
al., 2003; Trottier et al., 2006; Barbier et al., 2009). Lastly, sulfonation which is a 
minor reaction for most bile acids is the predominate conjugation mechanism of 
lithocholic acid (LCA), the most toxic bile acid. Sulfonation occurs through a class of 
cytosolic enzymes called sulfotransferases (SULT). The major bile acid 
sulfotransferase is SULT2A1, which almost exclusively sulfonates LCA (Huang et al., 
2010). 
 
The metabolic signaling function of bile acids has been shown in apoptosis, glucose 
homeostasis, cholesterol homeostasis, and as ligands for many nuclear hormone 
receptors (NHR) (Nguyen and Bouscarel, 2008; Carazo et al., 2017; Mueller et al., 
2017). The levels of specific bile acids in the bile acid pool are tightly controlled by 
many transporters and NHRs. In addition, these bile acids are capable of altering the 
expression of many other NHRs and transporters within the system through their 
action as NHR ligands (Rodrigues et al., 2014). For example, bile acids binding to the 




thereby increasing bile acid sulfonation (Saini et al., 2004; Fang et al., 2005; Wunsch 
et al., 2015). During cholestasis, however, there is a large increase in circulating bile 
acids, with a 10-fold increase in sulfated bile acids, a 666-fold increase in amidated 
bile acids, and a shift from glyco- to tauro-bile acids (Humbert et al., 2012).  
 
As DILI is one of the most frequent reasons for drug withdrawal, there is potential of 
DILI to be mediated through inhibition of bile acid amidation and sulfonation. We 
investigated the potential inhibition of 125 compounds on sulfonation (SULT2A1) and 




LC-MS grade acetonitrile, LC-MS grade formic acid, potassium phosphate (mono- 
and di-basic), adenosine triphosphate, and taurine were purchased from Fisher 
Scientific (Waltham, MA). 3'-phosphoadenosine-5'-phosphosulfate (PAPS) was 
purchased from R&D Systems (Minneapolis, MN). Lithocholic acid sulfate was 
purchased from Santa Cruz Biotechnology (Dallas, Texas). Lithocholic acid, cholic 
acid, and taurocholic acid were purchased from Steraloids (Newport, RI). Coenzyme 
A, magnesium chloride, dithiothreitol, clomiphene, pooled mixed gender human 
cytosol (Product #C2988, Lot #SLBP8169V) were purchased from Millipore Sigma 
(St. Louis, MO). Pooled mixed gender human S9 (Product #H0620.S9, Lot #1610015) 
was purchased from Sekisui XenoTech, LLC (Kansas City, KS). Test compounds 
were provided by Pfizer Inc (Groton, CT) as 30 mM solution in DMSO with final 





SULT2A1-catalyzed LCA sulfonation activity was determined in the absence and 
presence of test compound in a total assay volume of 50 μL. In a microcentrifuge tube 
was placed 50 mM potassium phosphate (pH 7.0), 1 μM PAPS, 1 μM LCA, and 
various concentrations of test compound. The reaction was started by the addition of 
human liver cytosol (0.5 mg/mL) and placed in a shaking water bath at 37oC for 30 
min and stopped by placing in boiling water for 30 sec. The mixture was centrifuged 
at 15,000 x g for 15 minutes to pellet the protein. Supernatant (10 μL) was then 
injected onto Waters XBridge C18 column (50 x 2.1 mm, 3.5 μm, Milford, MA) 
connected to a Shimadzu Prominence UFLC system (Shimadzu Corporation, Kyoto, 
Japan) coupled to Sciex 4500 Q-Trap ESI (Sciex, Framingham, MA, USA). Mobile 
phase A consisted of water with 0.1% formic acid; mobile phase B consisted of 
acetonitrile with 0.1% formic acid. At a flow rate of 0.5 mL/min, the column was 
equilibrated with 20% B. Sample was injected, held for 1 min at 20% B, then 
increased linearly to 95% B over 4 min, then held for 2 min. The column was then re-
equilibrated at 20% B for 2 minutes before the next injection. The mass spectrometer 
was operated in negative ion mode with the following settings: ISV, -4500; 
temperature, 500oC; DP, -65; EP, -10; CE, -65. LCA-S was measured through MRM 
mode (455.3→97.0) by comparing to a prepared calibration curve of LCA-S. Assays 
were performed in triplicate with the mean of the replicates being analyzed (SEM less 
than 10%). Clomiphene was used as a positive control for SULT2A1 inhibition.  
 
Test compounds were first screened for % inhibition of LCA sulfonation at a single 




were further screened at four additional concentrations (100 μM, 10 μM, 1 μM, and 
100 nM). Those observed to have an estimated IC50 value less than 100 μM were 
further analyzed at eight concentrations ranging from 300 μM to 100 nM.  
 
Amidation Assay 
Amidation activity was determined by measuring CA conjugation with taurine in the 
absence and presence of test compound in a total assay volume of 50 μL. In a 
microcentrifuge tube was placed 50 mM potassium phosphate (pH 7.0), 100 μM CA, 1 
μM coenzyme A, 2 mM taurine, 5 mM MgCl2, 5 mM ATP and various concentrations 
of test compound. The reaction was started by the addition of human liver S9 (0.3 
mg/mL) and placed in a shaking water bath at 37oC for 60 min and stopped by placing 
in boiling water for 30 sec. The mixture was then centrifuged at 15,000 x g for 15 
minutes to pellet the protein. The supernatant (10 μL) was then injected into Waters 
XBridge C18 column (50 x 2.1 mm, 3.5 μm, Milford, MA) connected to a Shimadzu 
Prominence UFLC system (Shimadzu Corporation, Kyoto, Japan) coupled to Sciex 
4500 Q-Trap ESI (Sciex, Framingham, MA, USA). Mobile phase A consisted of water 
with 0.1% formic acid; mobile phase B consisted of acetonitrile with 0.1% formic 
acid. At a flow rate of 0.5 mL/min, the column was equilibrated with 20% B. Sample 
was injected at 20% B, increased linearly to 50% B over 4 min, then increased to 90% 
B over 2 min and held for 2 min. The column was then re-equilibrated at 20% B for 2 
minutes before the next injection. The mass spectrometer was operated in negative ion 
mode with the following settings: ISV, -4500; temperature, 400oC; DP, -50; EP, -10; 
CE, -117. TCA was measured through MRM mode (514.7→79.9) by comparing to a 




of the replicates being analyzed (SEM less than 10%). No positive control was 
available for inhibition of CA-taurine amidation. 
 
Test compounds were first screened for % inhibition of CA amidation at a single 
concentration (300 μM), and those with >10% inhibition (<90% activity remaining) 
were further screened at four additional concentrations (100 μM, 10 μM, 1 μM, and 
100 nM). Those observed to have an estimated IC50 value less than 100 μM were 
further analyzed at eight concentrations ranging from 300 μM to 100 nM. 
 
Statistical Analysis 
Statistical Analysis was conducted using GraphPad Prism 7 software (La Jolla, CA). 
All concentrations values were first logged, and the concentrations of product were 
normalized between an inhibitor free reaction, and a reaction without cytosol or S9. 




Bile Acid Sulfonation 
The chromatographic conditions of LCA-S were optimized to ensure a swift run time 
with optimal peak shape, allowing for a retention time of 2.72 min (Figure 1A). The 
peak areas were converted to concentrations using a calibration curve. In order to 
account for day to day variability, the concentrations were normalized to an 
uninhibited reaction. Of the 125 compounds tested (Table 1) only nine showed 




Clomiphene, the positive control had an IC50 value of 9.26 μM, similar to a 
previously reported value (Bamforth et al., 1992). Several other compounds were 
strong inhibitors with IC50 values below 10 μM (Table 2). All the compounds except 
clomiphene have never been reported as inhibitors, and benzbromarone was the only 
compound to exhibit an IC50 value below 1 μM leading to possibilities as a positive 
control in future studies (Figure 2). A structurally similar compound, benziodarone, 
also showed strong inhibition with an IC50 value of 5.76 μM. The only structural 
difference between the two compounds is replacement of two bromine atoms on the 
benzene ring for two iodine atoms. Other notable inhibitors include benztropine (1.27 
μM), clemastine (5.00 μM), and phenoxybenzamine (7.87 μM). 
 
Bile Acid Amidation 
Taurocholic acid HPLC conditions were optimized to reduce run time and produce a 
sharp peak, producing a retention time of 3.02 min (Figure 1B). The peak areas were 
converted to concentrations using a calibration curve. In order to account for day to 
day variability, the concentrations were normalized to an uninhibited reaction. Very 
few enzyme incubations have been conducted with the BACS/BAAT system and all 
the previous work separated the two reactions  (Solaas et al., 2000). We developed a 
single assay to include both enzymes during our screening process. All 125 
compounds were tested, and only one compound showed inhibition below 100 μM, 
benoxaprofen, at 70.2 μM (Figure 3). 
 
Comparison of SULT2A1 Inhibitors 
The DILI classification of the nine sulfotransferase inhibitors were compared to the 




56% were classified as DILI, but in the drugs that were determined to be SULT2A1 
inhibitors only 44% were classified as DILI (Figure 4). This would indicate that there 
does not appear to a connection between DILI and inhibition of SULT2A1. The 
compound library was then further compared with a variety of values previously 
published by colleagues (Aleo et al., 2017). Inhibition of SULT2A1 was compared to 
molecular weight, log D (pH 7.4), and polar surface area (Figure 5). These values 
were graphed in order to determine approximate properties of SULT2A1 inhibitors 
and the following ranges were identified: molecular weight, 277-576; LogD, 1.2-4.2; 
polar surface area, 12-116. 
 
DISCUSSION 
The search for a mechanism of causation for drug induced liver injury and ways to 
prevent it are an ongoing effort within the pharmaceutical industry. Only a small 
subset of patients typically experience liver injury (Ortega-Alonso and Andrade, 
2018), and after drug treatment is ceased most patients’ biomarkers return to normal. 
However, some patients experience progressive and more permanent injury (Navarro 
and Senior, 2006). Often in these liver injury situations, a buildup of bile acids occurs, 
capable of breaking down the hepatocellular membrane, potentially leading to 
permanent injury (Scholmerich et al., 1984; Attili et al., 1986). In this study, we 
proposed that the inhibition of SULT2A1 and BACS/BAAT may be responsible for 
the hepatoxicity and liver injury experienced by patients taking DILI-associated drugs. 
To test this hypothesis, human liver cytosol and S9 were incubated with the drug of 




study, we are the first to report SULT2A1 inhibition with several new compounds and 
a novel BACS/BAAT inhibitor. 
 
While sulfonation is overall the least predominant form of bile acid conjugation, it is 
the predominate mechanism of detoxification of LCA, the most toxic bile acid (Huang 
et al., 2010). During the screening of 125 compounds, 9 inhibitors of SULT2A1 were 
found of which 4 were known DILI compounds. Most of these compounds were 
unknown inhibitors of SULT2A1. While there does not appear to be a general 
correlation between DILI and the inhibition of bile acid sulfonation, it is a potential 
mechanism of action of individual compounds. Zafirlukast, while not a strong 
inhibitor, has an unknown cause of the liver injury. The symptoms of zafirlukast liver 
injury are similar to those of cholestasis, and could potentially be linked to the 
inhibition of sulfonation. The information found from this experiment would warrant 
further investigation to determine the exact cause of zafirlukast hepatoxicity. Also, of 
note, was the compounds with IC50 values below that of clomiphene, the positive 
control. Our reported clomiphene IC50 values were within an acceptable range based 
on previous literature (Bamforth et al., 1992). These compounds would allow for 
future studies with more effective inhibition of SULT2A1. The inhibitors of 
SULT2A1 were graphed against the entire library of compounds with a variety of 
different properties to determine if the SULT2A1 inhibitors contain any similarities. 
The results in molecular weight, logD, and polar surface area do show unique 




weights and logD values that inhibit SULT2A1. This information will allow for future 
drug design for either avoiding inhibition or to intentionally inhibit SULT2A1. 
 
In this current study, we demonstrate a novel method for BACS/BAAT screening. 
While other methods have split the reaction between the two enzymes, we developed a 
single assay (Shonsey et al., 2005a; Shonsey et al., 2005b). The purpose is because the 
end product of BACS is necessary for BAAT to occur, and inhibition at either step 
will prevent the amidation of cholic acid. In terms of a potential DILI mechanism 
through inhibition, splitting the reaction is not necessary. There was a recently 
published study that attempted to develop a one-step amidation reaction but their 
results could not be replicated (Ogimura et al., 2017). We also attempted to test their 
methods and their compounds in our assay. We saw no inhibition with the compounds 
at 300 μM.  
 
While almost all compounds did not inhibit the BACS/BAAT pathway, we did find a 
single inhibitor benoxaprofen, which exhibited an IC50 of 70.2 μM. Benoxaprofen is a 
withdrawn nonsteroidal anti-inflammatory drug (NSAID). It is believed that the deaths 
were caused by bioaccumulation in the liver due to a toxic metabolite. While a weak 
inhibitor of amidation, it is possible that the inhibition of amidation could be a 
cumulative effect with the toxic metabolite leading to hepatotoxicity. Further studies 





Only a handful of compounds appeared to inhibit the conjugation of bile acids but it is 
still possible that drug perturbations to the bile acid pool could be the cause of liver 
injury. The drugs still could be altering the conjugation of bile acids through 
downregulation of transcription or translation of the enzymes involved. In addition, 
alterations of the bile acid pool could still occur, but depend more on the excretion and 
reabsorption of bile acids. Follow up research involving human cell lines examining 
transport, and gene expression would help to further understand the mechanism of 
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Figure 1. The MRM chromatograms of LCA-S (A) and TCA (B) with retention times 
of 2.72 and 3.02 min, respectively. LCA-S was measured at the m/z transition 
455.3→97.0 and TCA was measured at the m/z transition of 514.7→79.9. 
 
Figure 2. IC50 curves of all compounds with IC50 values less than 100 μM, sorted by 
lowest to highest IC50, left to right. Calculated by using Graphpad Prism 7, using non-
linear regression fit. 
 
Figure 3. IC50 curve of benoxaprofen inhibition of the BACS/BAAT system. IC50 
value of 70.2 μM with 95% confidence intervals from 45.6 μM – 107.8 μM. 
 
Figure 4. The percentage of drugs tests that were classified as DILI vs non-DILI in the 
total screening (A) and of those that were SULT2A1 inhibitors (B). 
 
Figure 5. Comparisons of the compounds SULT2A1 IC50 values vs molecular weight 
(A), logD at pH 7.4 (B), and polar surface area (C). 
 
Table 1. Alphabetical list of 125 compounds tested for inhibition of SULT2A1 and 
BACS/BAAT. The bolded compounds are known DILI compounds. 
 
Table 2. List of compounds with IC50 values less than 100 μM. The compound names 
in bold are known DILI compounds. Clomiphene was used as a positive control. All 











Figure 2.  














































































































































































Figure 5.  




































































abacavir chlorpheniramine flutamide nefazodone stavudine
acetylsalicylic acid cinchophen fluvoxamine nevirapine streptomycin
albuterol ciprofloxacin folic acid niacin sulfamethoxazole
alendronate clemastine guanethidine nimesulide sulindac
ambrisentan cyanocobalamin hydroxyurea nitrofurantoin tacrine
amikacin dacarbazine hydroxyzine nomifensine tamoxifen
amineptine deferoxamine indinavir nortriptyline tamsulosin
aminosalicylicacid diclofenac iproniazid orlistat tasosartan
amiodarone didanosine isoniazid oxybutynin tenofovir
atropine digoxin isoproterenol paliperidone terazosin
benoxaprofen dihydroergotamine kanamycin pamabrom ticrynafen
benzarone diphenhydramine ketoconazole paromomycin tipranavir
benzbromarone dobutamine labetalol pazopanib tolcapone
benziodarone doxylamine lamivudine penbutolol tolterodine L-tartrate
benztropine ebrotidine lapatinib perhexiline trihexyphenidyl
betaine ergocalciferol leflunomide phenazopyridine triprolidine hcl
bicalutamide erythromycin estolate liothyronine phenoxybenzamine troglitazone
biperiden esmolol loratadine phentolamine trovafloxacin
bosentan ethambutol mercaptopurine pirprofen valproicacid
bromfenac etodolac metaproterenol primaquine vancomycin
brompheniramine fenoprofen methimazole primidone verapamil
busulfan fexofenadine methotrexate procyclidine zafirlukast
carbamazepine fipexide methysergide protriptyline hcl zalcitabine
carbetapentane fluconazole metronidazole rifampin zidovudine














clomiphene 9.27 5.74 14.81
benzbromarone 0.73 0.33 1.50
benztropine 1.27 0.37 4.57
clemastine 5.00 2.65 9.05
benziodarone 5.76 2.22 12.90
phenoxybenzamine 7.87 4.10 15.00
perhexiline 43.67 30.73 60.91
zafirlukast 54.29 20.24 144.00
oxybutynin 61.46 37.10 101.80
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PBC  primary biliary cholangitis 
PSC  primary sclerosing cholangitis 
UDCA  ursodeoxycholic acid 
PPAR   peroxisome proliferator-activated receptor 
CYP  cytochrome P450 
C4  hydroxy-4-cholesten-3-one 
CA  cholic acid  
CDCA  chenodeoxycholic acid 
DCA  deoxycholic acid 
LCA  lithocholic acid 
BACS  bile acid coenzyme A synthetase 
BAAT  bile acid coenzyme A: amino acid N-acyltransferase  
UGT  uridine 5'-diphospho-glucuronosyltransferase 
SULT   sulfotransferase 
OCA  obeticholic acid 
ALP   alkaline phosphatase  
ALT   alanine aminotransferase 
ULN  upper limit of normal 
Wy-14,643  pirinixic acid  
GCDCA  glycochenodeoexycholic acid 
GCA   glycocholic acid 
GDCA  glycodeoxycholic acid 
TCA   taurocholic acid 
TCDCA           taurochenodeoxycholic acid 
TDCA   taurodeoxycholic acid 
TUDCA  tauroursodeoxycholic acid 
 
 






Cholestatic liver diseases, i.e. primary biliary cholangitis (PBC) and primary 
sclerosing cholangitis (PSC), result in the retention of bile acids, causing subsequent 
hepatotoxicity. Accumulation of toxic bile acids is a significant contributor of liver 
disease progression, often leading to cirrhosis, ultimately requiring a liver 
transplantation. Ursodeoxycholic acid (UDCA) and obeticholic acid are the only 
therapeutic options available, however they have limited efficacy or dose-limiting side 
effects, respectively. Alternative therapies are needed. The peroxisome proliferator-
activated receptor alpha (PPAR) is a nuclear receptor highly expressed in liver and it 
is a regulator of bile acid metabolism. Fenofibrate, a PPARα agonist, is FDA-
approved to reduce elevated cholesterol. Clinical data demonstrates that adjunct 
fenofibrate improved abnormal liver biochemistries for patients with PBC who are not 
responding to UDCA, however the role of fenofibrate on bile acid metabolism during 
cholestasis remains unknown.  We hypothesize that fenofibrate reduces bile acid 
toxicity during cholestasis via PPAR regulation. Adult patients with PBC or PSC 
taking UDCA (13-15 mg/kg/day) by mouth received adjunct fenofibrate (160 mg/day). 
Blood samples were used to measure serum liver enzymes and bile acid concentrations 
by standard clinical analyses and high-performance liquid chromatography and mass 
spectrometry, respectively. Treatment with adjunct fenofibrate reduced serum markers 
of cholestatic liver injury for patients with PBC or PSC. Addition of fenofibrate 
significantly reduced 7α-hydroxy-4-cholesten-3-one (C4), the bile acid precursor, as 
well as total, primary, and conjugated bile acids. Conclusions: Fenofibrate has anti-




glycine-conjugated pathways, suggesting a role of PPARα in bile acid amidation 
during cholestasis. Fenofibrate is a promising therapeutic option for patients with 
cholestasis and sub-therapeutic responses to UDCA monotherapy. These findings 





Hepatic bile acid secretion and bile formation are essential functions of the 
mammalian liver. Bile acids are important endogenous steroid-derived molecules 
responsible for maintaining cholesterol homeostasis, with critical roles in the 
absorption of dietary lipids and fat-soluble vitamins. Bile acids are also integrally 
involved in lipid solubilization and metabolic signaling. Hepatic bile acid synthesis 
and biliary excretion constitute the main routes for cholesterol removal from the 
human body. While bile acids serve as endogenous detergents for the intestinal 
absorption of dietary cholesterol, due to their detergent properties, they also have the 
potential to be inherently cytotoxic. Accumulation of bile acids in the liver can be 
toxic and lead to inflammation, fibrosis, cirrhosis, and eventually liver failure. In 
particular, the hydrophobic nature of bile acids induces cellular injury by breaking 
down cell membranes of hepatocytes (1, 2). An excess of intracellular bile acids 
increases mitochondrial membrane permeability, leading to cellular apoptosis or 
necrosis (3, 4). This physiochemical property of bile acids can be reduced through 
conjugation pathways involving taurine, glycine, sulfates, or glucuronides.   
In humans, bile acid synthesis occurs through one of two main pathways, with 
the most common pathway of synthesis occurring from cholesterol by the cytochrome 
P450 (CYP) enzymes, specifically Cytochrome P450 7A1 (CYP7A1) to 7α-hydroxy-
4-cholesten-3-one (C4), the bile acid precursor, leading to the synthesis of cholic acid 
(CA) or chenodeoxycholic acid (CDCA) by CYP8B1 and CYP27A1, respectively (5). 
The alternative pathway of bile acid synthesis bypasses C4, thus only produces CDCA 




CDCA undergo either conjugation to a polar group or metabolism into a secondary 
bile acid, i.e. deoxycholic acid (DCA) or lithocholic acid (LCA) by bacterial enzymes 
within the intestines (6-8). Amidation is one type of conjugation that occurs through 
sequential action of two enzymes: bile acid coenzyme A synthetase (BACS) in the 
endoplasmic reticulum or bile acid coenzyme A: amino acid N-acyltransferase 
(BAAT) in the cytosol (9). The process of amidation adds an amine, i.e. taurine or 
glycine, to the carboxylic acid moiety of the unconjugated bile acid, thereby 
enhancing aqueous solubility and decreasing toxicity. Alternatively, glucuronidation, a 
second form of conjugation, adds a glucuronide to one of several sites containing a 
hydroxyl moiety on the bile acid, resulting in a more hydrophilic and readily excreted 
compound. A specific uridine 5'-diphospho-glucuronosyltransferase (UGT) enzyme 
catalyzes the glucuronidation reaction; however, the specific UGT isoform involved 
depends on the site of glucuronidation. Lastly, sulfonation is a minor conjugation 
reaction that occurs predominately through sulfotransferase 2A1 (SULT2A1) and that 
sulfonates LCA almost exclusively (10).  
The peroxisome proliferator-activated receptors (PPAR) are a group of nuclear 
hormone receptors that act as ligand-activated transcription factors involved in many 
cellular functions including lipid metabolism (11), fatty acid oxidation (12), and 
importantly bile acid metabolism (13). PPARα is the predominate isoform in the liver, 
where it plays a central role in maintaining cholesterol, lipid, and bile acid 
homeostasis (reviewed in (14)) by regulating many genes responsible for human bile 
acid metabolism and transport, including CYP7A1 (15, 16), CYP27A1 (17, 18) , 




human apical sodium-dependent bile salt transporter (23). The expression of many of 
these genes is altered during cholestatic liver diseases. 
Cholestasis, including primary biliary cholangitis (PBC) and primary 
sclerosing cholangitis (PSC), results from an impairment or disruption of bile flow 
that causes an intracellular accumulation of toxic bile constituents, notably bile acids. 
Current treatments for PBC include ursodeoxycholic acid (UDCA) or obeticholic acid 
(OCA) while there are no FDA-approved treatment options for PSC. Approximately 
40% of patients with PBC have a sub-therapeutic response to UDCA, while patients 
taking OCA experience dose-limiting pruritus (24, 25). Furthermore, UDCA does not 
improve survival in patients with PSC, emphasizing urgent the need for alternative 
therapies. Fenofibrate belongs to the fibrate class of drugs and it is a PPARα agonist 
(26). While fenofibrate is FDA-approved to treat dyslipidemia, clinical data 
demonstrates that adjunct fenofibrate therapy improves liver function abnormalities in 
some patients with PBC and PSC who do not fully respond to UDCA monotherapy 
(27-31). The role of fenofibrate on bile acid metabolism during cholestasis, however, 
has not been evaluated. The results of our study show that fenofibrate reduces elevated 
liver enzymes during adult cholestasis, both PBC and PSC.  Importantly, we present 
direct evidence that fenofibrate favorably regulates bile acid metabolism during 
cholestasis and that fenofibrate shifts the bile pool towards a less toxic composition in 
humans. Furthermore, these findings provide an integral role of PPARα regulation on 






MATERIALS AND METHODS 
Chemicals  
Bile acids and deuterated internal standards (d4-CA, d4-CDCA, d4-DCA, and 
d4-LCA) were purchased from Steraloids Inc. (Newport, RI), C4 and d7-C4 were 
purchased from Toronto Research Chemicals (North York, ON, CA). Mass 
spectrometry (MS) grade solvents were purchased from Sigma-Aldrich (St. Louis, 
MO). A Synergi 4 μm Hydro-RP (100 x 2 mm) HPLC column and guard column were 
purchased from Phenomenex, Inc. (Torrance, CA).  
 
Human Serum Samples 
Serum or plasma from adult patients diagnosed with PBC (n=11) and PSC 
(n=9) who have received UDCA regimen (13-15 mg/kg/day) ± adjunct fenofibrate 
(160 mg/day) by mouth and have consented to have their blood samples de-identified 
and stored at the Yale University Liver Center Clinical Registry (New Haven, CT) 
were included in this study. These de-identified samples were determined to be 
exempt from the Institutional Review Board at Yale University (New Haven, CT) and 
the University of Rhode Island (Kingston, RI). Serum and plasma samples were used 
to measure liver enzymes and bile acid concentrations.  
 
Liver Enzyme Levels 
Serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate 




enzymatic methods (Yale New Haven Hospital, New Haven, CT). Patients with serum 
ALP values > 1.5x upper limit of normal (ULN) were included for analysis.  
 
Preparation of Serum Samples for High Performance Liquid Chromatography 
(LC)-MS/MS Analysis  
Bile acid concentrations were measured by HPLC-MS/MS methodology. 
Samples were prepared by adding internal standards to serum. To this mixture, ice 
cold acetonitrile was added, vortexed and centrifuged at 10,000 x g to precipitate and 
pellet the protein. Supernatant was collected, evaporated under air, and reconstituted 
in methanol:water (50:50). A standard curve (1 nM to 5 µM) for each bile acid and C4 
was prepared. To account for matrix effects of human serum, pooled (n=6) human 
serum (BioIVT, Westbury, NY) was charcoal stripped twice overnight with 0.25 mg 
of activated charcoal (Sigma-Aldrich) per mL of serum. The serum sample was then 
prepared in a similar manner as the patient samples. 
 
HPLC-MS/MS Measurement of Bile Acids 
Serum and plasma samples were analyzed using a Shimadzu Prominence 
UFLC system (Shimadzu Corporation, Kyoto, Japan) coupled to a Sciex 4500 Q-Trap 
ESI (Sciex, Framingham, MA, USA) under multiple reaction monitoring mode in a 
single HPLC-MS/MS method. Bile acids, their conjugates, and internal standards were 
measured in a single method, operated in negative ion mode. A volume of 15 µL of 
samples or standards were injected onto the column running a gradient method using 5 




acetate in methanol acidified with 0.01% formic acid, and acetonitrile at a flow rate of 
0.6 mL/min over 18 mins (Figure 1). Parameters of the mass spectrometer for bile acid 
quantification have been previously described (32). C4 and d7-C4 were analyzed in 
positive mode using a gradient method, 5 mM ammonium acetate in water with 0.01% 
formic acid, 5 mM ammonium acetate in methanol over 8 mins. The ion source 
voltage was 5500, declustering potential of 21 V, entrance potential of 10 V, collision 
energy of 27 V, cell exit potential of 6 V, with mass transitions of 401.6→383.6 and 
408.3→390.3 m/z for C4 and d7-C4 respectively (Figure 2). A standard curve (1 nM 
to 5 µM) for each bile acid and C4 was prepared and the lower limit of detection was 
1.0 nM to 5.0 nM. Values below the limit of detection were imputed using R Studio 
(Boston, MA). 
 
Data Analysis  
Bile acid concentrations are reported as average (nM) ± standard error of the 
mean (SEM). Total bile acid concentrations represent the sum of all bile acids 
measured. Total primary bile acids consist of CA and CDCA along with all respective 
conjugated species, while secondary bile acids include DCA and LCA with their 
respective conjugated species. The sum of all unconjugated bile acids includes the 
hydroxylated bile acids and UDCA. Total conjugated bile acids consist of all glyco- 
and tauro-conjugated bile acids along with LCA-S. The glyco- and tauro-conjugates 
are the sum of all glyco- and tauro-conjugates of CA, CDCA, DCA, LCA, and UDCA.  
The data were analyzed by Mann-Whitney tests in GraphPad Prism 8 (La Jolla, CA). 





Liver function enzymes 
Serum ALP is a liver enzyme that serves as a marker of cholestatic liver injury  
(33, 34). Recent pilot studies have shown that patients with PBC and a sub-therapeutic 
response to UDCA therapy experienced reduced serum ALP levels after adjunct 
treatment with fibrates (29, 35-40). In the current study, all patients in the PBC and 
PSC groups receiving UDCA monotherapy had serum ALP > 1.5xULN. Following 
adjunct treatment with fenofibrate, serum ALP levels were reduced by 66% in the 
PBC (442.4 ± 156.4 to 197.4 ± 41.9 U/L, p=0.06) and 58% in the PSC cohort (705.4 ± 
202.0 to 297.9 ± 103.5 U/L, p=0.05) (Figure 3A). Importantly, after treatment with 
fenofibrate, 30% of patients with PBC and 50% of patients with PSC had serum ALP 
values restored to normal ranges.   
Serum ALT, AST, and total bilirubin, serve as general markers of liver injury.  
Patients with PBC receiving UDA monotherapy experienced mild elevations in their 
serum ALT and AST levels that were reduced by adjunct fenofibrate (63.5 ± 14.9 to 
52.1 ± 10.2 U/L and 69.6 ± 17.6 to 52.5 ± 7.3 U/L, respectively.) shown in Figure 3B, 
3C. In the PSC cohort, significant reductions in elevated serum ALT and AST were 
observed (125.1 ± 10.8 to 51.4 ± 10.5 U/L and 126.4 ± 21.6 U/L to 51.9 ± 10.3 U/L, 
respectively). Following adjunct fenofibrate therapy significantly reduced evaluated 
total bilirubin levels in the PSC cohort (Fig. 3D). These results demonstrate the 
therapeutic efficacy of adjunct fenofibrate for patients with PBC or PSC and are 





Serum Bile Acid Concentrations in Patients with PBC 
A hallmark feature of cholestatic liver diseases is elevated (toxic) serum bile 
acid levels, leading to increased hepatotoxicity (1, 2). To determine the effects of 
adjunct fenofibrate therapy on bile acid metabolism during cholestasis, adult patients 
with PBC (before fenofibrate n=11, after fenofibrate n=7) receiving UDCA (13-15 
mg/kg/day) ± fenofibrate (160 mg/day) had their blood samples measured for bile acid 
concentration by LC-MS/MS. A summary of all bile acids measured in the current 
study is presented in Table 2. The addition of fenofibrate therapy for patients with 
PBC reduced the total bile acid concentrations by 47% (Figure 4A). In particular, the 
primary bile acids decreased by 53% (Figure 4B), and, interestingly, remained 
relatively unchanged as a percent of the total bile acid composition. The bile acid 
precursor C4, produced by CYP7A1, is the classical pathway of bile acid synthesis 
and then be enzymatically converted to CA or CDCA. The concentration was 
significantly reduced in fenofibrate-treated patients by 48% (p = 0.008, Figure 4F). In 
conjunction with the reduction in C4, a shift towards CDCA synthesis is observed as 
CDCA can then only be produced by the alternative pathway (Figure 4G).  
In addition to a shift in bile acid composition favoring CDCA (over CA), a 
similar shift was observed in the ratio of glycine to taurine conjugates (Figure 4H). 
Adjunct fenofibrate treatment reduced total glycine- and taurine-conjugated bile acids 
by 41% and 53%, respectively (Figure 5Aand 6A), resulting in approximately a 70% 
shift favoring glycine- over taurine-conjugated bile acids (Figure 4H). Adjunct 
fenofibrate treatment reduced GCDCA, GCA, and GDCA by 34%, 58%, and 18% of 




treatment with adjunct fenofibrate reduced the taurine-conjugates, specifically TCA 
and TCDCA by 70% and 45%, respectively (Figure 6A and 6B). Interestingly, the 
contribution of TCDCA reduced by half, however the contribution of TCDCA to the 
total bile acid pool remained unchanged, thereby supporting the shift towards CDCA 
(Figure 6E). Furthermore, the total amount of TDCA remained relatively unchanged, 
and thus the percent of TDCA within the bile acid pool increased accordingly by 2-
fold (Figure 6D and 6E). Secondary bile acids exhibited a 16% decrease, resulting in a 
1.5-fold increase in the relative percentage of secondary bile acids to the total bile acid 
pool (Figure 4C and 6G). Addition of fenofibrate also decreased the total percent of 
unconjugated bile acids by 40%, however, no major change in the contribution of 
unconjugated bile acids in the bile acid pool composition was observed (Figure 4E). 
Lastly for the bile acids which constituted less than 5% of the total bile acid pool, 
minor changes were observed in HCA (+102%), LCA-S (+38%), TLCA (+24%) and 
GLCA (-32%). 
 
Serum Bile Acid Concentrations in Patients with PSC 
To date, there are no FDA-approved therapies for PSC. As such, the use of 
adjunct fenofibrate during PSC is a potential therapy.  A summary of all bile acids 
measured in patients with PSC is presented in Table 3. In the PSC cohort (before 
fenofibrate n= 9, after fenofibrate n=7), total bile acid concentrations were reduced by 
72% following the addition of fenofibrate (Figure 7A). Importantly, the primary bile 
acids decreased by 81%, which reduced their contribution in the bile acid pool from 




in the PSC group (-46%), which also resulted in a shift towards CDCA synthesis and 
corresponding change in ratio from 0.73:1 to 1.1:1 (CDCA:CA) (Figure 7F and 6G). 
This result may be explained by the 55% increase in absolute CDCA, resulting in a 
5.6-fold increase in the relative contribution to the total bile acid pool.  
In addition to adjunct fenofibrate therapy leading to a shift towards CDCA 
synthesis, and in a manner similar to the PBC cohort, the ratio of glycine to taurine 
conjugates shifted favoring glycine conjugated bile acids by 25% (Figure 7H), which 
is likely due to a 77% reduction in glycine-conjugates and 84% reduction in taurine-
conjugated bile acids (Figure 8A and 9A). In particular, adjunct fenofibrate reduced 
GCDCA, GCA, and GDCA by 24%, 20%, and 18% of the total bile acid pool, 
respectively (Figure 8B, 8C, 8D, and 8E). Treatment with adjunct fenofibrate also 
reduced the taurine-conjugates, specifically TCA and TCDCA by 87% and 84%, 
respectively (Figure 9B and 9C). An unexplained effect of adjunct fenofibrate 
treatment was an increase in secondary bile acids by 42%, resulting in a 5-fold 
increase in their contribution to the bile acid pool (Figure 7C, G). Adjunct fenofibrate 
treatment also increased unconjugated bile acids by 9%, raising their relative 
contribution to the total bile acid pool to 33% (Figure 7E). Lastly, of the bile acids that 
constituted less than 5% of the total bile acid pool, changes in the following bile acids 
occurred: DCA (+103%), GDCA (+36%) (Figure 8D), TDCA (14%) (Figure 9D), 





Similarities and differences in the bile acid composition between PBC and PSC 
cohorts 
Both cohorts of patients included in this study had elevated bile acids while 
receiving UDCA monotherapy, before adjunct fenofibrate treatment. As hypothesized, 
the total bile acid pool and the composition of the bile acid pool decreased greatly 
following fenofibrate therapy, in both cohorts. Specifically, both patient groups had 
similar amounts of C4 present before fenofibrate and after adjunct fenofibrate therapy, 
the C4 levels were reduced by approximately the same percentage amounts (-44%). 
The reductions in C4 were also reflected in the shift away from CA towards CDCA in 
both cohorts. In the PSC cohort, 91% of the bile acids exist in a conjugated state while 
only 58% exist a conjugated state in the PBC cohort. In particular, conjugated bile 
acids were largely decreased by adjunct fenofibrate treatment, resulting in a shift 
towards glycine from taurine conjugation in patients with PBC and PSC. These 
changes were driven by a greater reduction in the glycine and taurine conjugated CAs, 
than their CDCA counterparts. In both patient cohorts, secondary bile acids constituted 
a rather small portion of the bile acid pool remaining below 12% and 3% before 
treatment in PBC patients and PSC patients, respectively. After treatment, in both 
groups, the secondary bile acids increased to 17% and 11% in PBC and PSC, 
respectively. LCA-S and HCA, while minor bile acids, were increased in both groups 
of patients by adjunct fenofibrate treatment. 
Notable differences among the bile acids between the two cohort, however, 
were also found first, in the PBC cohort, primary bile acids constitute 45% of primary 




bile acid pool. Minor differences between the two groups, with the PSC cohort having 
increases in DCA, secondary bile acids, and unconjugated bile acids but decreases in 
patients with PBC. 
 
CONCLUSIONS 
Over the past several years the search for alternative therapies to treat 
cholestatic liver diseases has continued and the use of fibrates has emerged as a 
potential therapy. However, mainly for patients with PBC, leaving very few treatment 
options for patients with PSC and the disease often progresses to liver failure. The 
major effects of fibrates on cholestatic liver diseases is largely attributed to the 
activation of PPAR. In particular the PPARα isoform plays an important role in 
transcriptional activation of gene expression of bile acid metabolizing enzymes. In this 
study, we hypothesized that fenofibrate’s anticholestatic effects could be mediated 
through detoxifying bile acids via PPARα regulation of bile acid metabolizing 
enzymes. To test this hypothesis, we studied patients with PBC or PSC receiving 
UDCA monotherapy before and after adjunct fenofibrate therapy. While the majority 
of previous pilot studies have shown the efficacy of fibrates in reducing elevated 
serum liver enzymes during cholestasis, the effects of fenofibrate on bile acid 
metabolism in cholestatic patients have not yet been reported, despite bile acid toxicity 
being a hallmark characteristic of cholestatic liver diseases. Results of this study 
demonstrate the reduction in total, primary, conjugated and unconjugated bile acids 




Data from the current study shows that treatment with adjunct fenofibrate 
decreases all of the major biochemical biomarkers of cholestasis, in addition to 
normalizing ALP levels in 30% of patients with PBC and 50% of patients with PSC. 
The reductions in ALP are in agreement with recently published work using fibrates 
showing approximately 50% reductions in ALP, including one study involving adjunct 
bezafibrate in patients with PBC (39) and another study with bezafibrate and 
fenofibrate in patients with PSC (41). While the study conducted by Corpechot et al., 
showed anticholestatic effects of bezafibrate in patients with PBC, bezafibrate is not 
an FDA approved drug in the U.S and, furthermore, it is a non-selective PPAR agonist 
(42). In addition, most of these previous pilot studies did not report on serum bile acid 
concentrations except for C4, which was reduced by bezafibrate thus the need to 
examine bile acids in patients with cholestasis and treated with adjunct fenofibrate (39, 
40). 
The overall results from this study demonstrate that the use of fenofibrate 
effectively reduced serum bile acids in patients with PBC and PSC. The serum values 
of total bile acid concentrations for patients with PBC and PSC prior to fenofibrate 
treatment obtained in the current study are similar to those measured in previous 
studies (43). In the current study, the majority of the reductions in bile acids was a 
result of decreased conjugated bile acids and not the unconjugated forms of CA, 
CDCA, DCA, or LCA. Specifically, reductions in C4 concentrations by nearly 50% 
were observed in both cohorts, and these findings agree with previous literature 
reports that describe CYP7A1 mRNA downregulation in response to activation of 




caused by a decrease in hepatocyte nuclear factor 4 alpha, a known CYP7A1 
transcription factor (16). A direct effect of C4 reductions were observed through a 
reduction of CA in both cohorts after adjunct fenofibrate treatment. The alternative 
pathway of bile acid synthesis produces CDCA by bypassing via CYP27A1 and 
CYP7B1. This shift in bile acid synthesis may explain the observed increase in CDCA 
but not CA, as CA can only be synthesized through the traditional pathway. A shift 
towards the alternative pathway by fenofibrate is further supported in the decreased 
ratio of CA:CDCA in both patient cohorts after adjunct fenofibrate treatment. 
Together these findings suggest that either the alternate pathway could be upregulated 
or that the primary pathway through C4 was reduced, or a combination of the two 
occurred following adjunct fenofibrate therapy. 
Typically, conjugation reduces bile acid toxicity and the goal for treatment 
during cholestasis includes reducing elevated bile acids and inducing a shift in the 
total bile acid pool towards conjugation to decrease the hydrophobicity. The results 
presented herein show a reduction in total bile acids was achieved by adjunct 
fenofibrate treatment as well as reductions in glycine- and taurine-conjugated bile 
acids, a result likely explained by the downregulation of BAAT mRNA and activity, a 
key enzyme involved in bile acid amidation which has been shown to be PPARα-
dependent in mice (44). In combination with a downregulation of the amidation-
mediated conjugation reactions, the decrease observed in conjugated bile acids by 
adjunct fenofibrate may also be partially accounted for by the reduction of 
unconjugated bile acid substrate necessary for the conjugation reaction to occur. In 




treatment a further shift towards glycine approaching the 3:1 (glycine:taurine) ratio 
observed in non-cholestatic patients (43) was observed. Additionally, sulfonation of 
LCA, while a relatively small conjugation pathway, in both patient cohorts, was found 
to be upregulated, a finding that is in agreement with previous report of a PPARα 
response element identified upstream of the SULT2A1 gene (22). Lithocholic acid, a 
monohydroxy bile acid, is the most toxic bile acid, thus sulfonation of this particular 
bile acid by adjunct fenofibrate treatment is clinically very important. 
While this study showed significant reductions in clinical biomarkers of 
cholestasis and large reductions in many of the serum bile acids, there are limitations 
of this study.  First, this study is a retrospective single-arm study examining the effects 
of adjunct fenofibrate vs. patients pre-treated with UDCA monotherapy. Second, the 
sample size was limited. For some patients, baseline blood samples were not available, 
and other patients have yet to have follow up post-fenofibrate therapy. Third, the lack 
of consistent time on treatment, measurement of biomarkers over time, and a washout 
period reduced the longitudinal aspect of this study. Lastly, more clinical endpoints 
need to measured, including pruritus, liver stiffness, stages of liver disease, or impact 
of adjunct therapy on liver transplant time. Additional studies of a prospective nature 
are necessary to address these needs, nevertheless our study provides compelling 
preliminary data to support larger clinical studies. 
In conclusion, we present in vivo evidence that adjunct treatment with 
fenofibrate reduces serum liver enzyme abnormalities in patients with PBC and PSC. 
Importantly, this is one of the first to demonstrate adjunct fenofibrate therapy reduces 




reduced after adjunct fenofibrate therapy, indicating that bile acid synthesis may be 
downregulated through PPARα activation in both PBC and PSC cohorts. Additionally, 
decreases in glycine- and taurine-conjugated bile acids are observed, with 
concentrations restoring patient serum values closer towards a 3:1 ratio of glycine to 
taurine, as observed in non-cholestatic patients (43). Collectively, the findings 
presented herein demonstrate that adjunct fenofibrate treatment reduces bile acid 
toxicity and, furthermore, suggests that PPARα is integrally involved in bile acid 
regulation during cholestasis. PPARα is a potential target for the treatment of 
cholestasis, for both PBC and PSC, especially for those patients who are non-
responders to UDCA or OCA. While our study has a limited sample size, combined 
with the inherent large interindividual variation in endogenous serum bile acid 
concentrations, a larger prospective study is necessary. Nevertheless, the findings 
reported in this study suggest that liver diseases that are impacted by bile acid toxicity 
such as PBC and PSC and not therapeutically responding to UDCA monotherapy may 
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Figure 1. A LC-MS chromatogram of 17 bile acids and 4 deuterated internal 
standards. Standards were spiked into double charcoal stripped pooled human serum 






Figure 2. A LC-MS chromatogram of 7α-hydroxy-4-cholesten-3-one (C4) and d7-C4 
internal standard. Standards were spiked into double charcoal stripped pooled human 





Figure 3. Treatment with fenofibrate reduces liver injury in patients with PBC and 
PSC. Serum levels of: (A) alkaline phosphatase, (B) alanine aminotransferase, (C) 
aspartate aminotransferase and (D) total bilirubin were measured by standard 






Figure 4. Treatment with adjunct fenofibrate alters serum bile acid concentrations in 
patients with PBC: (A) total bile acids, (B) primary bile acids (C) secondary bile acids, 
(D) conjugated bile acids, (E) unconjugated bile acids, and (F) C4 were measured by 
LC-MS/MS.  Ratios of the bile acids and their conjugates are shown in (G) and total 
glycine and taurine conjugate shown in (H). Data are reported as average ± SEM; 











































































































































































Figure 5. Treatment with fenofibrate alters serum glycine conjugated bile acid 
concentrations in patients with PBC: A) total glycine bile acids, B) GCA C) GCDCA, 
and D) GDCA were measured by LC/MS/MS. Ratios of glycine conjugated before 




























































































Figure 6. Treatment with adjunct fenofibrate alters serum taurine conjugated bile acid 
concentrations in patients with PBC: (A) total taurine bile acids, (B) TCA (C) 
TCDCA, and (D) TDCA were measured by LC-MS/MS. Ratios of taurine conjugated 


























































































Figure 7. Treatment with fenofibrate alters serum bile acid concentrations in patients 
with PSC: (A) total bile acids, (B) primary bile acids (C) secondary bile acids, D) 
conjugated bile acids, (E) unconjugated bile acids, and (F) C4 were measured by LC-
MS/MS.  Ratios of the bile acids and their conjugates are shown in (G) and total 








































































































































































Figure 8. Treatment with fenofibrate alters serum glycine conjugated bile acid 
concentrations in patients with PSC: (A) total glycine bile acids, (B) GCA (C) 
GCDCA, and (D) GDCA were measured by LC/MS/MS. Ratios of glycine conjugated 





























































































Figure 9. Treatment with fenofibrate alters serum taurine conjugated bile acid 
concentrations in patients with PSC: (A) total taurine bile acids, (B) TCA, (C) 
TCDCA, and (D) TDCA were measured by LC/MS/MS. Ratios of taurine conjugated 


























































































Table 1. Demographics of patients with cholestasis in both cohorts.  
 











(Median) 54 (51-67) 58 (47-68)  
Age 
(Median) 40 (24-54) 45 (33-66) 
Male 1 0  Male 8 5 
Female 10 9  Female 1 2 
White 8 6  White 5 6 
Black 1 0  Black 3 0 
Hispanic  2 2  Hispanic  0 0 







Table 2. Serum bile acid concentrations (nM ± SEM) in patients with PBC before 
(UDCA monotherapy) and after adjunct fenofibrate therapy. Statistical significance is 
indicated by *p < 0.05, **p < 0.01 versus before levels. 
 
PBC Before PBC After
 (Mean ± SEM)  (Mean ± SEM)
CA 102.15 ± 56.22 41.58 ± 23.10
CDCA 205.83 ± 77.41 263.48 ± 79.16
DCA 1393.65 ± 543.80 1107.00 ± 466.34
GCA 4066.77 ± 2009.31 1716.42 ± 479.81
GCDCA 5787.39 ± 2685.61 3823.73 ± 1176.24
GDCA 1114.27  ± 318.70 912.25 ± 321.21
GLCA 207.85 ± 43.63 153.60 ± 45.14
HCA 23.13 ± 9.05 46.78 ± 12.46
HDCA 366.31 ± 148.24 340.20 ± 202.12
LCA 172.07 ± 36.74 157.58 ± 33.49
LCA-S 20.55 ± 3.54 28.28 ± 10.08
TCA 2253.62 ± 1227.61 673.45 ± 203.24
TCDCA 1756.63 ± 812.84 968.96 ± 276.06
TDCA 260.99 ± 70.27 259.76 ± 109.15
TLCA 33.42 ± 6.77 41.36 ± 18.72
TUDCA 2293.15 ± 1617.56 1166.17 ± 332.05
UDCA 10851.73 ± 6037.62 5917.64 ± 1254.84
C4 177.70 ± 28.23 91.80 ± 9.14**
Total 30909.50 ± 12428.28 17618.23 ± 2330.57
Total Primary 14195.52 ± 6277.72 7534.39 ± 1910.95
Total Secondary 3569.11 ± 999.77 3000.02 ± 999.05
Total Unconjugated 13114.86 ± 6054.22 7874.25 ± 1558.22
Total Conjugated 17794.64 ± 7788.18 9743.97 ± 2320.69
Total Taurine 6597.81 ± 3522.25 3109.70 ± 816.65

















Table 3. Serum bile acid concentrations (nM ± SEM) in patients with PSC before 
(UDCA monotherapy) and after adjunct fenofibrate therapy. Statistical significance is 
indicated by *p < 0.05 
 
PSC Before PSC After
 (Mean ± SEM)  (Mean ± SEM)
CA 217.75 ± 206.94 100.08 ± 37.97
CDCA 167.40 ± 64.63 258.76 ± 78.27
DCA 271.77 ± 134.95 551.36 ± 249.57
GCA 17913.34 ± 8016.82 3027.81 ± 1072.87
GCDCA 14853.69 ± 5022.65 3747.66 ± 1148.19
GDCA 519.76 ± 169.80 704.45 ± 258.43
GLCA 71.32 ± 33.49 54.14 ± 22.71
HCA 9.88 ± 5.19 26.94 ± 8.12*
HDCA 92.09 ± 59.29 110.55 ± 32.20
LCA 38.14 ± 22.63 31.89 ± 8.93
LCA-S 6.29 ± 2.73 14.93 ± 5.84
TCA 8794.85 ± 4589.10 1146.90 ± 521.63
TCDCA 4676.26 ± 2145.08 725.38 ± 265.87
TDCA 143.32 ± 43.37 163.45 ± 68.46
TLCA 15.16 ± 7.54 12.67 ± 6.29
TUDCA 3242.15 ± 2086.89 636.14 ± 241.91
UDCA 3875.75 ± 3376.13 3991.68 ± 1168.19
C4 237.38 ± 92.08 128.36 ± 20.47
Total 54908.91 ± 21039.65 15304.81 ± 3166.69
Total Primary 46633.18 ± 19530.57 9033.53 ± 2391.28
Total Secondary 1157.84 ± 362.71 1643.47 ± 571.26
Total Unconjugated 4672.77 ± 3326.68 5071.27 ± 1392.51
Total Conjugated 50236.14 ± 19990.74 10233.54 ± 2772.53
Total Taurine 16871.73 ± 7444.46 2684.54 ± 931.31
Total Glycine 33358.12 ± 12815.23 7534.07 ± 1983.28
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